To determine whether these effects of seribantumab affected tumor growth, we tested the effect of seribantumab as a single-agent in the cisplatin-responsive BL0440 PDX model55, which expresses high levels of HER2 and ErbB3 (Fig. 1). Here, ERBB3 is linked to neoplasm.